Literature DB >> 10956312

Angiotensin converting enzyme inhibition: from viper to patient.

M Komajda1, M C Wimart.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956312      PMCID: PMC1766532          DOI: 10.1136/heart.84.suppl_1.i11

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  10 in total

1.  ACE inhibitors still the drug of choice for heart failure--and more.

Authors:  E Topol
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

2.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Authors:  K Swedberg; M Pfeffer; C Granger; P Held; J McMurray; G Ohlin; B Olofsson; J Ostergren; S Yusuf
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712

5.  Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  F Locatelli; I R Carbarns; G Maschio; J F Mann; C Ponticelli; E Ritz; D Alberti; M Motolese; G Janin; P Zucchelli
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

6.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

Authors:  B Dahlöf; K Pennert; L Hansson
Journal:  Am J Hypertens       Date:  1992-02       Impact factor: 2.689

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Differences in tissue angiotensin II-forming pathways by species and organs in vitro.

Authors:  M Akasu; H Urata; A Kinoshita; M Sasaguri; M Ideishi; K Arakawa
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.